Innospec Stock Price, News & Analysis (NASDAQ:IOSP)

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec declared a Semi-Annual dividend on Tuesday, May 7th. Shareholders of record on Tuesday, May 21st will be given a dividend of $0.50 per share on Thursday, May 30th. This represents a yield of 1.18%. The ex-dividend date of this dividend is Monday, May 20th. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) released its quarterly earnings results on Tuesday, August, 6th. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.02. The specialty chemicals company had revenue of $362.40 million for the quarter, compared to analysts' expectations of $371.20 million. Innospec had a return on equity of 15.11% and a net margin of 6.10%. The firm's revenue was up 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.80 earnings per share. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Innospec.

Innospec will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 analysts have issued twelve-month target prices for Innospec's shares. Their forecasts range from $83.00 to $95.00. On average, they anticipate Innospec's stock price to reach $89.00 in the next twelve months. This suggests that the stock has a possible downside of 1.7%. View Analyst Price Targets for Innospec.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

News articles about IOSP stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innospec earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned headlines about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Innospec.

Innospec saw a drop in short interest in September. As of September 30th, there was short interest totalling 342,200 shares, a drop of 10.1% from the August 30th total of 380,700 shares. Based on an average daily trading volume, of 115,700 shares, the days-to-cover ratio is currently 3.0 days. Currently, 1.4% of the shares of the stock are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), KURARAY CO LTD/ADR (KURRY), Ingevity (NGVT), Univar (UNVR), Balchem (BCPC), Olin (OLN), Chemours (CC), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), NVIDIA (NVDA), Applied Materials (AMAT), B&G Foods (BGS), Colgate-Palmolive (CL), Emerson Electric (EMR), UnitedHealth Group (UNH), XPO Logistics (XPO), Zayo Group (ZAYO) and Adobe (ADBE).

Innospec's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Kirr Marbach & Co. LLC IN (0.71%), State of Alaska Department of Revenue (0.08%) and Diversified Trust Co (0.01%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, David Earl Williams, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Kirr Marbach & Co. LLC IN. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $90.52.

Innospec has a market capitalization of $2.22 billion and generates $1.48 billion in revenue each year. The specialty chemicals company earns $85 million in net income (profit) each year or $4.83 on an earnings per share basis. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]